Butensky & Cohen Financial Security’s AbbVie ABBV Stock Holding History

Butensky & Cohen Financial Security’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-31,356	Closed	-$5.08M	–	96
2022 Q1	$5.08M	Sell	31,356 -3,069	-9%	-$446K	1.79%	2
2021 Q4	$4.66M	Buy	34,425 +317	+0.9%	+$37.4K	1.66%	8
2021 Q3	$3.68M	Buy	34,108 +627	+2%	+$71.6K	1.46%	22
2021 Q2	$3.77M	Buy	33,481 +41	+0.1%	+$4.62K	1.5%	20
2021 Q1	$3.62M	Buy	33,440 +27	+0.1%	+$2.89K	1.5%	19
2020 Q4	$3.58M	Buy	33,413 +1,483	+5%	+$143K	1.62%	7
2020 Q3	$2.8M	Sell	31,930 -504	-2%	-$47.5K	1.48%	29
2020 Q2	$3.18M	Buy	32,434 +1,609	+5%	+$142K	1.81%	3
2020 Q1	$2.35M	Buy	30,825 +25	+0.1%	+$2.13K	1.77%	9
2019 Q4	$2.73M	Sell	30,800 -667	-2%	-$55.4K	1.56%	25
2019 Q3	$2.38M	Buy	31,467 +5,973	+23%	+$410K	1.43%	35
2019 Q2	$1.85M	Buy	25,494 +3,365	+15%	+$264K	1.24%	47
2019 Q1	$1.78M	Buy	22,129 +3,625	+20%	+$297K	1.29%	42
2018 Q4	$1.71M	Buy	18,504 +445	+2%	+$39.1K	1.51%	32
2018 Q3	$1.71M	Buy	18,059 +484	+3%	+$45.9K	1.37%	42
2018 Q2	$1.63M	Buy	17,575 +120	+0.7%	+$11.7K	1.38%	39
2018 Q1	$1.65M	Sell	17,455 -6,185	-26%	-$679K	1.45%	37
2017 Q4	$2.29M	Sell	23,640 -803	-3%	-$75.7K	1.89%	9
2017 Q3	$2.17M	Sell	24,443 -5,150	-17%	-$392K	1.93%	12
2017 Q2	$2.15M	Sell	29,593 -70	-0.2%	-$4.71K	1.93%	7
2017 Q1	$1.93M	Sell	29,663 -85	-0.3%	-$5.34K	1.77%	19
2016 Q4	$1.86M	Buy	29,748 +1,595	+6%	+$97.4K	1.72%	23
2016 Q3	$1.78M	Buy	28,153 +490	+2%	+$31.7K	1.71%	21
2016 Q2	$1.71M	Sell	27,663 -10	-0%	-$609	1.68%	22
2016 Q1	$1.58M	Buy	27,673 +838	+3%	+$46.7K	1.52%	28
2015 Q4	$1.59M	Buy	26,835 +1,432	+6%	+$82.5K	1.57%	27
2015 Q3	$1.38M	Buy	25,403 +1,304	+5%	+$84.9K	1.48%	28
2015 Q2	$1.62M	Buy	24,099 +485	+2%	+$31.7K	1.63%	24
2015 Q1	$1.38M	Buy	23,614 +2,165	+10%	+$131K	1.37%	38
2014 Q4	$1.4M	Buy	+21,449	New	+$1.35M	1.41%	35

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Butensky & Cohen Financial Security's ABBV Position: Q2 2022 in Review

Butensky & Cohen Financial Security sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 31,356 shares — an estimated $5.08M sold.

Butensky & Cohen Financial Security first reported a position in ABBV in Q4 2014 and held it in 30 quarters. The position peaked at $5.08M in Q1 2022. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

Butensky & Cohen Financial Security reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
Butensky & Cohen Financial Security sold 31,356 AbbVie shares in Q2 2022, an estimated $5.08M.
Butensky & Cohen Financial Security first reported a position in AbbVie in Q4 2014 and held it in 30 quarters.
Butensky & Cohen Financial Security's AbbVie position peaked at $5.08M in Q1 2022.
3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Butensky & Cohen Financial Security's 13F filing for Q2 2022, filed 14 Jul 2022.